Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /home/elsalysb/public_html/modules/simplenews/simplenews.tokens.inc on line 119
Inolimomab (LEUKOTAC®) | Elsalys Biotech Skip to main content

Inolimomab (LEUKOTAC®)

Thu, 01/09/2020 - 13:00
  • The French National Agency for the Medicines and Health Products Safety (ANSM) granted a Temporary Authorisation for Use (ATU) so-call

Mon, 02/18/2019 - 09:46

Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)

Wed, 01/23/2019 - 15:00
  • Follow-up of INO-107 Phase III study patients up to 8.5 years is the first long term analysis of a randomized study in acute steroid
Thu, 04/05/2018 - 09:00
  • ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to

Thu, 10/12/2017 - 17:00
  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC®

Thu, 03/15/2018 - 17:00
  • A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute g

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.

The website encountered an unexpected error. Please try again later.